Malaysia-Singapore (MASPORE) leukaemia study group: From common history to successful collaboration

• DOI: 10.1016/j.phoj.2020.03.009
• Publication Date: 2020-03-24T22:27:48Z
• Authors: Hany Ariffin; Syaza Ab Rahman; Sheng Hoay Leong; Edwynn Kean-Hui C...; Hai Peng Lin; Thuan Chong Quah; Allen Eng-Juh Yeoh
• Keywords: Regimen

The 1970s marked the beginning of childhood cancer services in Malaysia and Singapore, two neighbours South-East Asia. Between 1995 2002, utilized a treatment regimen based on Dutch DCOG 7 German BFM protocols for children with acute lymphoblastic leukaemia (ALL), whilst Singapore collaboration Hong Kong employed HK-ALL 1997 protocol, ALL 95. In overall 6-year event-free survival (EFS) stood at 56%, while 5-year EFS was 79%. Formal between began 2003. first collaborative trial seminal MASPORE ALL2003 study which single PCR-based minimal residual disease marker to risk stratify patients according severity, used 3-drug induction non-high-risk patients. This effort resulted an improvement both countries, 80%, 88%. showed that could be appropriately tailored risk, anthracycline-free strategy did not compromise outcome majority (86%) follow-up study, ALL2010 focused delivering therapy more intensive those high-risk group reducing intensity standard intermediate groups. also took into consideration IKZF1 gene deletion (IKZF1del) moved these higher category. Increasing IKZF1del reduction cumulative incidence relapse (CIR) from 30 13%, improved 69 91%. studied TPMT NUDT15 variants its patient population optimize thiopurine dosing. As moves next phase (MASPORE ALL2020), precision medicine risk-adapted remain cornerstone strategies ALL, especially era increased recognition late effects amongst survivors cancer. Future therapies will likely focus further targeted as molecularly distinct subtypes become known.